Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, announces that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (Nasdaq: RSLS). The post-merger company will trade at the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol “HIND.” Vyome is building a healthcare platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions.
Read the full article: Vyome Closes Merger Transaction //
Source: https://www.businesswire.com/news/home/20250814305554/en/Vyome-closes-Merger-Transaction-Will-Trade-on-Nasdaq-as-HIND-Tomorrow